Halifax-based Sound Blade Medical has raised $24 million in Series A funding, co-led by Amzak Health and Lumira Ventures, with participation from Invest Nova Scotia. The funds will advance clinical validation and regulatory approvals for its handheld ultrasound-guided histotripsy device.
Histotripsy is a non-invasive, non-thermal ultrasound technology that liquefies targeted tissue without surgery, reducing recovery times and complications. CEO Jeremy Brown, Ph.D., says the investment accelerates Sound Blade’s mission to bring this precision therapy to patients.
Want to know more? Check out the source code on PR Newswire.